RU2006134695A - Пероральная композиция с пролонгированным высвобождением молсидомина для лечения атеросклероза - Google Patents
Пероральная композиция с пролонгированным высвобождением молсидомина для лечения атеросклероза Download PDFInfo
- Publication number
- RU2006134695A RU2006134695A RU2006134695/15A RU2006134695A RU2006134695A RU 2006134695 A RU2006134695 A RU 2006134695A RU 2006134695/15 A RU2006134695/15 A RU 2006134695/15A RU 2006134695 A RU2006134695 A RU 2006134695A RU 2006134695 A RU2006134695 A RU 2006134695A
- Authority
- RU
- Russia
- Prior art keywords
- hours
- molsidomine
- oral composition
- released
- solid oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Claims (5)
1. Применение молсидомина или одной из его фармацевтически приемлемых солей в форме твердой пероральной композиции с пролонгированным высвобождением действующего вещества, эффективной в течение 24 ч, для изготовления лекарства для профилактики или замедления развития атеросклероза.
2. Применение по п.1 твердой пероральной композиции с пролонгированным высвобождением действующего вещества, эффективной в течение 24 ч, отличающееся тем, что указанная композиция имеет следующую скорость растворения in vitro, измеренную спектрофотометрически при 286 или 311 нм, 50 об/мин в 500 мл 0,1н. HCl при 37°С, согласно способу, описанному в European Pharmacopoeia, 3 изд. (или U.S.P. XXIV):
от 15 до 25% молсидомина, высвобожденного через 1 ч,
от 20 до 35% молсидомина, высвобожденного через 2 ч,
от 50 до 65% молсидомина, высвобожденного через 6 ч,
от 75 до 95% молсидомина, высвобожденного через 12 ч,
более 85% молсидомина, высвобожденного через 18 ч,
более 90% молсидомина, высвобожденного через 24 ч,
причем пиковая концентрация молсидомина в плазме крови достигается in vivo через 2,5-5 ч, предпочтительно через 3-4 ч после введения указанной формы, и имеет значение от 25 до 40 нг/мл плазмы.
3. Применение по п.1 или 2, отличающееся тем, что композиция содержит от 14 до 24 мг, предпочтительно 16 мг молсидомина на дозированную единицу и предназначена для ежедневного введения.
4. Применение по любому из пп.1 и 2, отличающееся тем, что твердую пероральную композицию вводят пациентам, страдающим от стенокардии.
5. Применение по п.3, отличающееся тем, что твердую пероральную композицию вводят пациентам, страдающим от стенокардии.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0403534A FR2868314B1 (fr) | 2004-04-05 | 2004-04-05 | Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables |
| FR04/03534 | 2004-04-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006134695A true RU2006134695A (ru) | 2008-05-20 |
| RU2388475C2 RU2388475C2 (ru) | 2010-05-10 |
Family
ID=34944920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006134695/15A RU2388475C2 (ru) | 2004-04-05 | 2005-04-01 | Пероральная композиция с пролонгированным высвобождением молсидомина для лечения атеросклероза |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7754715B2 (ru) |
| EP (1) | EP1732565B8 (ru) |
| JP (1) | JP5117847B2 (ru) |
| KR (1) | KR101162385B1 (ru) |
| CN (1) | CN1938032B (ru) |
| AU (1) | AU2005239799B2 (ru) |
| BE (1) | BE1016580A3 (ru) |
| BR (1) | BRPI0509642A (ru) |
| CA (1) | CA2562287C (ru) |
| CY (1) | CY1117614T1 (ru) |
| DK (1) | DK1732565T3 (ru) |
| ES (1) | ES2567576T3 (ru) |
| FR (1) | FR2868314B1 (ru) |
| HK (1) | HK1092736A1 (ru) |
| HR (1) | HRP20160479T1 (ru) |
| HU (1) | HUE029199T2 (ru) |
| IL (1) | IL178440A0 (ru) |
| IT (1) | ITTO20050220A1 (ru) |
| MA (1) | MA28518B1 (ru) |
| MD (1) | MD4080C1 (ru) |
| NO (1) | NO336913B1 (ru) |
| NZ (1) | NZ550341A (ru) |
| PL (1) | PL1732565T3 (ru) |
| RS (1) | RS54791B1 (ru) |
| RU (1) | RU2388475C2 (ru) |
| SI (1) | SI1732565T1 (ru) |
| UA (1) | UA88461C2 (ru) |
| WO (1) | WO2005107761A1 (ru) |
| ZA (1) | ZA200608219B (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2617494T3 (es) * | 2012-05-31 | 2017-06-19 | G. Pohl-Boskamp Gmbh & Co. Kg | Inducción de arteriogénesis con un donador de óxido nítrico tal como nitroglicerina |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
| FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
| US6472390B1 (en) * | 2001-11-13 | 2002-10-29 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| KR100464876B1 (ko) * | 2001-11-15 | 2005-01-06 | 학교법인 인제학원 | 동충하초의 코르디세핀을 함유하는 항혈전제 조성물 |
| WO2010062256A1 (en) * | 2008-11-27 | 2010-06-03 | Nanyang Polytechnic | Process and system for automatic identification of the larvae of aedes albopictus and aedes aegypti |
-
2004
- 2004-04-05 FR FR0403534A patent/FR2868314B1/fr not_active Expired - Lifetime
-
2005
- 2005-04-01 JP JP2007506708A patent/JP5117847B2/ja active Active
- 2005-04-01 US US10/599,634 patent/US7754715B2/en active Active
- 2005-04-01 PL PL05755780T patent/PL1732565T3/pl unknown
- 2005-04-01 KR KR1020067020582A patent/KR101162385B1/ko active IP Right Grant
- 2005-04-01 AU AU2005239799A patent/AU2005239799B2/en active Active
- 2005-04-01 SI SI200532067A patent/SI1732565T1/sl unknown
- 2005-04-01 DK DK05755780.3T patent/DK1732565T3/en active
- 2005-04-01 ZA ZA200608219A patent/ZA200608219B/xx unknown
- 2005-04-01 ES ES05755780.3T patent/ES2567576T3/es active Active
- 2005-04-01 HU HUE05755780A patent/HUE029199T2/en unknown
- 2005-04-01 EP EP05755780.3A patent/EP1732565B8/fr active Active
- 2005-04-01 RS RS20160307A patent/RS54791B1/sr unknown
- 2005-04-01 BR BRPI0509642-1A patent/BRPI0509642A/pt not_active Application Discontinuation
- 2005-04-01 MD MDA20060241A patent/MD4080C1/ru active IP Right Grant
- 2005-04-01 CA CA2562287A patent/CA2562287C/fr active Active
- 2005-04-01 NZ NZ550341A patent/NZ550341A/en unknown
- 2005-04-01 WO PCT/EP2005/003531 patent/WO2005107761A1/fr active Application Filing
- 2005-04-01 UA UAA200610515A patent/UA88461C2/ru unknown
- 2005-04-01 RU RU2006134695/15A patent/RU2388475C2/ru active
- 2005-04-01 CN CN2005800107845A patent/CN1938032B/zh active Active
- 2005-04-04 BE BE2005/0173A patent/BE1016580A3/fr active
- 2005-04-04 IT IT000220A patent/ITTO20050220A1/it unknown
-
2006
- 2006-10-02 MA MA29367A patent/MA28518B1/fr unknown
- 2006-10-04 NO NO20064510A patent/NO336913B1/no unknown
- 2006-10-04 IL IL178440A patent/IL178440A0/en active IP Right Grant
-
2007
- 2007-01-02 HK HK07100028.9A patent/HK1092736A1/zh unknown
-
2016
- 2016-05-04 HR HRP20160479TT patent/HRP20160479T1/hr unknown
- 2016-06-02 CY CY20161100486T patent/CY1117614T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU709641B2 (en) | Oral fast-dissolving compositions for dopamine agonists | |
| US20050038062A1 (en) | Methods and materials for the treatment of pain comprising opioid antagonists | |
| WO2004037190A3 (en) | Modified release compositions of milnacipran | |
| RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| JP2005512995A5 (ru) | ||
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2010518122A5 (ru) | ||
| CA2601289A1 (en) | Once-a-day oxycodone formulations | |
| HUP0203680A2 (hu) | Szabályozott hatóanyag-leadású hidrokodon készítmények | |
| CA2661759A1 (en) | Buprenophine-wafer for drug substitution therapy | |
| ES2610469T3 (es) | Nuevas formulaciones farmacéuticas útiles en el tratamiento del insomnio | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| JP2005506367A5 (ru) | ||
| WO2010019915A1 (en) | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2005528430A5 (ru) | ||
| JP2023506545A (ja) | アゴメラチンを含有する経粘膜治療システム | |
| JP2007529564A5 (ru) | ||
| CA2486859A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
| RU2006137330A (ru) | Пероральные матричные композиции, содержащие ликарбазепин | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| Alsarra et al. | Clinical evaluation of novel buccoadhesive film containing ketorolac in dental and post-oral surgery pain management | |
| JP4090997B2 (ja) | ペリンドプリルの口内分散性薬剤組成物 | |
| JP5561885B2 (ja) | ミルタザピンの新しい配合物 |